Materials and methods
In this study, 3,215 samples of pregnant women were analyzed using rapid tests "Determine HIV1/2". Vertical transmission was estimated by PCR in newborns from those who were HIV positive. HIV-1 Resistance to ARVs, subtypes and CRFs were determined through ViroSeq kit using the ABI PRISM 3130 sequencer.
Results
In this study, 12.26% (394/3215) of the pregnant women were diagnosed HIV-positive, 0.52% (2/388) overall residual rate of transmission was identified with rates of 1.75% (2/114) among mothers under prophylaxis and 0.00% (0/274) for those under HAART. Genetic mutations have also been isolated that induce resistance to ARVs like M184V, Y115F, K103N, Y181C, v179E, G190A, etc. And there were subtypes and circulating recombinant forms (CRF) of HIV-1 such as: CRF06_CPX (58.8%), CRF02_AG (35.3%) and subtype G (5.9%).
Conclusion
Antiretroviral drugs reduce the residual rate of HIV vertical transmission. However, they cause mutations that induce resistance of HIV to antiretroviral therapy. Resistance to ARV therefore requires a permanent dialogue between clinicians, prescribers, pharmacists, and the creation of a network of monitoring and surveillance of drug resistance in Burkina Faso.
